Beximco Pharmaceuticals (DHA:BXPHARMA) Interest Expense : BDT-839 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Beximco Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was BDT -289 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was BDT-839 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Beximco Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was BDT 1,890 Mil. Beximco Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was BDT -289 Mil. Beximco Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 was 6.54. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beximco Pharmaceuticals Interest Expense Historical Data

The historical data trend for Beximco Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Interest Expense Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-1,013.05

-983.20

-805.87

-925.60

-1,241.66

Beximco Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-333.51	-320.77	-276.40	-273.95	-289.03

Beximco Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-839 Mil.

Beximco Pharmaceuticals (DHA:BXPHARMA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beximco Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was BDT-289 Mil. Its Operating Income for the three months ended in Mar. 2024 was BDT1,890 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was BDT1,604 Mil.

Beximco Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	1889.959	/	-289.03
	=	6.54

The higher the ratio, the stronger the company's financial strength is.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » Interest Expense

Traded in Other Exchanges

BXP:UK R2WA:Germany

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines